DOC
Healthpeak Properties, Inc.
$22.33
+0.59 (+2.71%)
At close · Jul 16
Market Cap
$15.39B
Shares
689,419,702
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$22.33
Open$21.80
Day$21.78–22.35
52W$15.43–22.35
Avg vol 30d6.3M
Short int27.1M · 3.9% float · 3.6d
Short vol55%
Last earningsAug 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 5, 2026
Scheduled
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Low
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+24%
above
Price vs 50-day avg
+10%
above
RSI (14)
70
neutral
MACD trend
Negative
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+11%
trailing
6-month return
+27%
trailing
YTD return
+41%
this year
Relative strength
+18%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $20 › 200d $18 — 50d above 200d
Institutional flow
Distributing
97 of 760 funds reported for Jun 30 · net -699.6K sh shares · +9 new
Insider flow
Distributing
Net -$213.7K over 90 days · 100% sells
Short interest
Falling
3.94% of float · ▼ -1.8% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
760 holders — near 3-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+5%
Y/Y
EPS growth
−72%
Y/Y
Valuation
P/E 69.8
in line
Buyback
$306.0M
remaining
Balance sheet
$9.4B
net debt
Quant / Vol
risk profile
Volatility
30%
annualized · 1-yr
Max drawdown
−17%
past year
ATR
2.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Equibles Research
All DOC research
Guidance & track record
Beat or met 3 of last 5
Latest guidance
· from the Earnings Call filed Mar 31, 2026
FFO as adjusted per share impact from Janus Living IPO proceeds
· once fully invested and stabilized
Non-GAAP
$0.04
Guided vs delivered
· last 5 settled
Diluted earnings per common share
full year 2025
$0.10
Miss −64.3%
Diluted earnings
full year 2024
$0.36
Beat +24.1%
Diluted earnings per common share
full year 2023
$0.56
Beat +3.7%
Diluted earnings per common share
full year 2022
$0.92
Beat +50.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+24%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
70
Neutral
MACD trend
Negative
Bearish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $20 › 200d $18 — 50d above 200d
Institutional flow
Distributing
97 of 760 funds reported for Jun 30 · net -699.6K sh shares · +9 new
Insider flow
Distributing
Net -$213.7K over 90 days · 100% sells
Short interest
Falling
3.94% of float · ▼ -1.8% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
760 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $15
Now $22 · 100%
52-wk high $22
vs 200-day avg +24%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| acquisitions closed prior to IPO | $700M | Q1 2026 call | — |
| active proposals and tours | 113,000 | Q1 2026 call | — |
| average annual escalators | 3% | Q1 2026 call | — |
| Baylor cancer center campus size | 458,000 | last 2 quarters call | — |
| cash re-leasing spreads on renewals | 5.4% | Q1 2026 call | — |
| cash re-leasing spreads on renewals prior quarter | 5.4% | prior quarter call | — |
| cash re-leasing spreads on renewals since merger | 5.8% | since merger call | — |
| current year FFO non-GAAP | $240M | current year call | — |
| dividend yield | 7.5% | Q1 2026 call | — |
| FFO as adjusted per share non-GAAP | $0.45 | Q1 2026 call | — |
| Healthpeak market value of Janus Living stake | $5.7B | Q1 2026 call | — |
| Healthpeak ownership of Janus Living | 81.6% | Q1 2026 call | — |
| Janus Living adjusted EBITDA growth non-GAAP | 42% | Q1 2026 call | — |
| lab leases executed | 141,000 | Q1 2026 call | — |
| lab leases under LOI | 355,000 | Q1 2026 call | — |
| lab LOI on currently vacant space | 75% | Q1 2026 call | — |
| lab total occupancy | 77.7% | Q1 2026 call | — |
| leasing commissions saved | $5M | prior quarter call | — |
| leasing costs as percent of annual rents | 10% | Q1 2026 call | — |
| net debt-to-EBITDA | 5.4 | Q1 2026 call | — |
| new leasing percent of lab leases | 92% | Q1 2026 call | — |
| new leasing percent of lab LOI | 80% | Q1 2026 call | — |
| new senior unsecured delayed draw term loan | $400M | Q1 2026 call | — |
| outpatient leases executed | 1.1M | Q1 2026 call | — |
| outpatient leases executed since April | 318,000 | since April 2026 call | — |
| outpatient leases under LOI | 700,000 | Q1 2026 call | — |
| renewals signed since merger | 10M | since merger call | — |
| same-store NOI growth average | 3.5% | last 5 years call | — |
| secured mortgages repaid | $103M | January 2026 call | — |
| signed leases and letters of intent | 62,000 | Q1 2026 call | — |
| stock buyback | $100M | April 2026 call | — |
| tenant retention | 79% | Q1 2026 call | — |
| total occupancy | 91% | Q1 2026 call | — |
| Lab cash releasing spreads on renewals non-GAAP | -1.7% | Q4 2025 | — |
| Lab renewal retention | 72% | Full Year 2025 | — |
| Net Debt to Adjusted EBITDAre non-GAAP | 5.2 | Q4 2025 | — |
| Non-refundable entry fee cash collections | $153M | Full Year 2025 | — |
| Outpatient Medical cash releasing spreads on renewals non-GAAP | 4.4% | Q4 2025 | — |
| Outpatient Medical renewal retention | 79% | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
REIT - Healthcare Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DOC
this stock
Healthpeak Properties, Inc.
|
$15.39B | +41.4% | +4.5% | 69.8 | 3.9% |
|
WELL
Welltower Inc.
|
$170.47B | +30.6% | +35.6% | 120.1 | 2.7% |
|
VTR
Ventas, Inc.
|
$46.72B | +23.6% | +18.5% | 174.7 | 4.7% |
|
OHI
Omega Healthcare Investors Inc
|
$14.85B | +14.2% | +13.2% | 24.0 | 4.7% |
|
AHR
American Healthcare REIT, Inc.
|
$10.91B | +20.9% | +9.1% | 95.9 | 10.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DOC | +3.5% | +11.2% | +27.1% | +4.4% | +41.4% |
| SPY | -0.1% | +0.1% | +9.0% | +0.5% | +10.1% |
| vs SPY | +3.7% | +11.1% | +18.1% | +3.8% | +31.3% |
Capital returns
Latest dividend
$0.102
/ share · ex Jun 15, 2026
Paid (TTM)
$1.122
/ share · 11 payouts
Dividend yield (TTM, derived)
5.02%
Buyback program
· as of May 6, 2026
Authorized
$500.00M
Spent (derived)
$194.00M
Remaining
$306.00M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
765880
CUSIP
42250P103
13F (30d)
104 filings
88 filers
Visit website
Investor relations